Danaher (DHR) Stock Price, News & Analysis

Company Overview

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs. Danaher’s operating companies deliver equipment and consumables used in sample preparation, molecular and cellular analysis, clinical diagnostics, water quality testing and other applied testing workflows, often combining hardware with software and service offerings to provide end-to-end solutions for customers.

Founded in 1969, Danaher has grown through organic development and acquisitions to build a diversified group of technology-oriented businesses. The company is headquartered in Washington, D.C., and serves customers worldwide across North America, Europe, Asia and other global markets. Danaher is also known for its emphasis on continuous improvement and operational excellence through the Danaher Business System, and it is governed by a board of directors and an executive leadership team. The company is publicly traded on the New York Stock Exchange under the ticker DHR.

Key Stats

• Today's Range: $171.14 to $174.95
• 50-Day Range: $161.95 to $198.58
• 52-Week Range: $160.93 to $242.80
• Volume: 3.00 million shs
• Average Volume: 5.15 million shs
• Market Capitalization: $121.82 billion
• P/E Ratio: 33.29
• Dividend Yield: 0.93%
• Price Target: $238.65
• Consensus Rating: Moderate Buy

Danaher Stock Analysis - MarketRank™

Danaher scored higher than 95% of companies evaluated by MarketBeat, and ranked 25th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Danaher has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Danaher has a consensus price target of $238.65, representing about 38.7% upside from its current price of $172.12.

Amount of Analyst Coverage

Danaher has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 8.07%

Earnings Growth

Earnings for Danaher are expected to grow by 8.07% in the coming year, from $8.43 to $9.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Danaher is 33.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Danaher is 33.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.26.

Price to Earnings Growth Ratio

Danaher has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Danaher has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.36% of the float of Danaher has been sold short.

Short Interest Ratio / Days to Cover

Danaher has a short interest ratio ("days to cover") of 1.45, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Danaher has recently increased by 5.00%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Danaher has a dividend yield of 0.93%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Danaher has only been increasing its dividend for 2 years.

Dividend Coverage

The dividend payout ratio of Danaher is 30.95%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Danaher will have a dividend payout ratio of 17.56% next year. This indicates that Danaher will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.16

News Sentiment

Danaher has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for Danaher this week, compared to 10 articles on an average week.

Search Interest

41 people have searched for DHR on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.

MarketBeat Follows

16 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Danaher insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.80% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.05% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 4/24 Dividend: 3/27/2026
• Ex-Dividend for 4/24 Dividend: 3/27/2026
• Last Earnings: 4/20/2026
• Dividend Payable: 4/24/2026
• Today: 5/24/2026
• Next Earnings (Estimated): 7/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Industrial Conglomerates
• Current Symbol: NYSE:DHR
• CIK: 313616
• Web: www.danaher.com
• Phone: (202) 828-0850
• Fax: 202-828-0860
• Employees: 60,000
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Danaher: $238.65
• High Price Target: $275.00
• Low Price Target: $200.00
• Potential Upside/Downside: +38.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.17
• Trailing P/E Ratio: 33.29
• Forward P/E Ratio: 20.42
• P/E Growth: 2.3
• Net Income: $3.61 billion
• Net Margins: 14.89%
• Pretax Margin: 17.51%
• Return on Equity: 10.91%
• Return on Assets: 6.94%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 1.87
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: $24.57 billion
• Price / Sales: 4.96
• Cash Flow: $11.38 per share
• Price / Cash Flow: 15.13
• Book Value: $74.82 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 707,770,000
• Free Float: 631,332,000
• Market Cap: $121.82 billion
• Optionable: Optionable
• Beta: 0.81